Long-term efficacy and safety of belimumab in children with systemic lupus erythematosus: a meta-analysis of real-world data
ReumatologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Rheumatology (Oxford, England)
- Publicado em
- 5 mai 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Long-term efficacy and safety of belimumab in children with systemic lupus erythematosus: a meta-analysis of real-world data
Thy Phuong Anh Le, El-Wui Loh, Ka-Wai Tam
Descritores MeSH
- Immunosuppressive Agents
- Lupus Erythematosus, Systemic
- Antibodies, Monoclonal, Humanized
- Child
- Remission Induction
- Severity of Illness Index
- Treatment Outcome
- Lupus Nephritis
- Glucocorticoids
- Humans
Veja também
Estudos relacionados
- II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment
- Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials
- Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
- Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials